Clinical Utility Evaluations
Clinical Utility Evaluations are comprehensive health technology assessments for complex genetic disorders and syndromes, which evaluate the impact of genetic testing on patient outcomes, diagnostic thinking, clinical decision making, and family members. These reports include the Hayes Clinical Utility Score, an overall rating of the strength and direction of the body of evidence for clinical utility of genetic testing for a specific indication.
Clinical Utility Evaluations provide evidence-based support for the development of coverage policy, utilization management, and evidence-based clinical practices. Used in conjunction with our Laboratory Insights database, these reports provide the critical evidence context to make decisions around multi-gene panel tests. Reports are reviewed annually up to 5 years post publication to determine if there is new literature or evidence that would impact a change in rating and warrant an updated report.
This report evaluates the clinical utility of prenatal whole genome sequencing and prenatal whole exome sequencing to improve diagnosis and inform pregnancy and post-pregnancy patient management where fetal abnormalities have been detected by ultrasound or other testing.
This report evaluates the clinical utility of pharmacogenetic and pharmacogenomic testing for (1) gene variants to predict risk of opioid dependency in patients being treated for pain or (2) gene variants to improve treatment of patients with diagnosed opioid use disorder (OUD).
This report evaluates the clinical utility of liquid biopsy tests for colorectal cancer (CRC) screening to reduce CRC morbidity and mortality.
This report evaluates the clinical utility of pharmacogenetic testing for CYP2D6 gene variants prior to prescribing codeine or tramadol to improve opioid treatment–related outcomes in pediatric patients with organic causes of pain.
Pharmacogenetic and Pharmacogenomic Testing for Opioid Treatment for Pain in Adults – Selected Single-Gene Variants and Pharmacogenomic Panels
This report evaluates the clinical utility of pharmacogenetic testing for:
CYP2D6 gene variants prior to prescribing codeine or tramadol
Single-gene variants in the CYP2D6, CYP3A…
This report evaluates the
This report evaluates the clinical utility of pharmacogenetic testing for OPRM1 and/or COMT gene variants to improve opioid treatment–related outcomes in patients with organic causes of pain.
This report evaluates the clinical utility of genetic screening of newborns for risk of hearing loss.
Genetic Testing for Common Forms of Hereditary Thrombophilia in Pediatric Patients with Unprovoked Venous Thromboembolism
This report evaluates the of genetic testing for common forms of hereditary thrombophilia in pediatric patients with unprovoked venous thromboembolism (VTE).